Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;63(2):346-51.
doi: 10.1002/art.30107.

The incidence of gastrointestinal perforations among rheumatoid arthritis patients

Affiliations

The incidence of gastrointestinal perforations among rheumatoid arthritis patients

Jeffrey R Curtis et al. Arthritis Rheum. 2011 Feb.

Abstract

Objective: Gastrointestinal (GI) perforation has emerged as a novel safety concern in relation to medications used to treat rheumatoid arthritis (RA). This study was undertaken to characterize the incidence and risk factors for GI perforation in RA patients.

Methods: Using administrative databases of a large US health plan, we identified RA patients treated with biologic agents, methotrexate (MTX), oral glucocorticoids, and nonsteroidal antiinflammatory drugs (NSAIDs). Additional risk factors we evaluated included diverticulitis. Hospitalization with GI perforation was identified using a validated algorithm. Incidence rates and risk factors were evaluated using Cox proportional hazards models.

Results: Among 40,841 RA patients, 37 hospitalizations with GI perforation were identified. The rate of GI perforation among patients currently being treated with biologic agents who were also receiving oral glucocorticoids was higher (1.12 per 1,000 person-years [95% confidence interval (95% CI) 0.50-2.49]) than for patients being treated with biologic agents who were not also receiving glucocorticoids (0.47 per 1,000 person-years [95% CI 0.22-0.98]) or for patients being treated with MTX who were also receiving glucocorticoids (0.87 per 1,000 person-years [95% CI 0.36-2.10]). Neither biologic agents nor MTX was significantly associated with GI perforation, in contrast to current treatment with glucocorticoids and NSAIDs together (hazard ratio 4.7 [95% CI 1.9-12.0]) or glucocorticoids alone (hazard ratio 2.8 [95% CI 1.3-6.1]). Diverticulitis also was a strong risk factor (hazard ratio 9.1 [95% CI 3.1-26.4]). Seventy percent of patients with GI perforation received glucocorticoids, had antecedent diverticulitis, or both.

Conclusion: GI perforation is an uncommon but serious adverse event among RA patients. Because a majority of patients with GI perforation were being treated with glucocorticoids or had previously experienced diverticulitis, these individuals should be considered at higher risk.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Van Vollenhoven RFKE, Furie R, Blesch A, Wang C, Curtis JR. Gastrointestinal Safety in Patients with Rheumatoid Arthritis Treated with Tocilizumab: Data From Roche Clinical Trials. American College of Rheumatology ACR/ARHP Annual Scientific Meeting; Philadelphia, PA. 2009.
    1. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007 Sep;56(9):2896–904. - PMC - PubMed
    1. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003 Nov 1;158(9):915–20. - PubMed
    1. Curtis J, Chen S, Werther W, John A, Johnson D. Validation of ICD-9-CM to Identify GI Perforation in Administrative Claims Data Among Rheumatoid Arthritis Patients. International Society of Pharmacoepidemiology; Brighton, U.K: 2010. - PMC - PubMed
    1. Rothman KJ. Epidemiology. New York: Oxford University Press; 2002.

Publication types